Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6864095/
https://ncbi.nlm.nih.gov/pubmed/31745135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-53327-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars